Nipocalimab not checked

Johnson & Johnson (Janssen) · JNJ-80202135 · JNJ-86507083

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 2/3 trial completes
Trials
11 active
23 in total · 13 in the EU
Targets
—
None known yet

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Nipocalimab will be administered as an intravenous infusion.”In the company’s words, NCT05912517 on ClinicalTrials.gov
Tested for
Myasthenia Gravis (3 trials), Thrombocytopenia, Neonatal Alloimmune (2 trials), Sjogrens Syndrome, Hemolytic Disease of the Fetus and Newborn, Lupus Erythematosus, Systemic, Warm Autoimmune Hemolytic Anemia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Main trialPhase 3
“The purpose of this study is to evaluate the efficacy and safety of nipocalimab compared to placebo in participants with generalized myasthenia gravis (gMG). The purpose of the subcutaneous substudy is to evaluate how well it works in the body (pharmacodynamic \[PD\]) when given as an injection under the skin (subcutaneous) compared to when given through a vein (intravenous) in participants with gMG.”In the company’s words, NCT04951622 on ClinicalTrials.gov
Other names
JNJ-80202135 · JNJ-86507083 · M281 · M281/JNJ-80202135

Other drugs for Myasthenia Gravis

All 37 drugs for Myasthenia Gravis

Coming up9

Changes1

Last 90 days

Trials23

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 17 Nov 2023 A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Phase 3Active, not recruiting 4 Feb 2027 Nipocalimab in Moderate to Severe Sjogren's Disease
Phase 3Recruiting 5 Aug 2027 A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Phase 3Recruiting 28 Sep 2027 Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Phase 3Recruiting 15 Dec 2027 A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Phase 3Recruiting 6 Dec 2028 A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
Phase 3Recruiting 5 Dec 2029 A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Phase 2/3Active, not recruiting 2 Feb 2025 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
Phase 2/3Recruiting 15 Dec 2026 Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2/3Recruiting 30 Jun 2027 A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Phase 1Recruiting 16 Feb 2027 A Study to Assess Nipocalimab Concentrations in Breast Milk of Healthy Lactating Women
Phase 2Completed 10 Aug 2022 A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis
Phase 2Completed 23 Oct 2023 A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)
Phase 2Completed 30 Apr 2024 A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus
Phase 2Completed 5 Aug 2024 A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)
Phase 2Completed 29 Aug 2024 A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
Phase 2Completed 4 Sep 2025 A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies
Phase 2Withdrawn 28 Feb 2028 A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis
Phase 1Completed 26 May 2022 A Study of Nipocalimab in Healthy Male and Female Participants
Phase 1Completed 27 May 2022 A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants
Phase 1Completed 9 Sep 2022 A Study of JNJ-80202135 in Healthy Chinese Adult Participants
Phase 1Completed 4 Oct 2023 A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants
Phase 1Ended not given A Phase I, Open-Label, Two-Part, Multiple-Dose, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Delivered Subcutaneously via Syringe and Prefilled Syringe Autoinjector in Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Nipocalimab

Following is part of Solo: you see every change to Nipocalimab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in